Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report.

Wilcox L, Van Dril E

Journal of the American Pharmacists Association : JAPhA9 Jul 2024Cited by 4 (Europe PMC)

PMID38992739DOI10.1016/j.japh.2024.102185PepBankPUB-38992739

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanCase report or seriesSafety outcome
In a post-thyroidectomy patient on levothyroxine, thyroid stimulating hormone was suppressed after subcutaneous semaglutide was started and titrated.
In plain wordsIn one woman without a thyroid gland, a thyroid hormone marker fell after she started semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTSH suppression after starting semaglutide
Study
n = 1
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
This patient experienced suppressed TSH levels following initiation and titration of subcutaneous semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this case report is to describe a case of suppressed thyroid stimulating hormone levels after initiation of a subcutaneous semaglutide in a post-total thyroidectomy patient managed with levothyroxine in order to highlight the need for closer monitoring of these patients and further…
Summary · context
The patient described in the case underwent a total thyroidectomy in 2015 with stable thyroid hormone replacement requirements with levothyroxine for 5 years until the initiation and titration of subcutaneous semaglutide.
Report a problemFND-3899273901
02HumanCase report or seriesSafety outcome
In a post-thyroidectomy patient, the fall in TSH after starting semaglutide therapy required a 25 percent reduction of the levothyroxine dose.
In plain wordsIn one woman without a thyroid gland, her thyroid medicine dose had to be cut by 25 percent after she started semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLevothyroxine dose reduction needed
Study
n = 1
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
Levothyroxine dose reduction
25 percent
post-thyroidectomy patient
Source sentences
Summary
The reduction in thyroid stimulating hormone (TSH) after starting GLP-1 RA therapy necessitated a 25 percent dose reduction of levothyroxine from her original dose.
2 context sentences(design, population, supporting numbers)
Summary · context
The objective of this case report is to describe a case of suppressed thyroid stimulating hormone levels after initiation of a subcutaneous semaglutide in a post-total thyroidectomy patient managed with levothyroxine in order to highlight the need for closer monitoring of these patients and further…
Summary · context
The patient described in the case underwent a total thyroidectomy in 2015 with stable thyroid hormone replacement requirements with levothyroxine for 5 years until the initiation and titration of subcutaneous semaglutide.
Report a problemFND-3899273902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.